NASDAQ OMX

Novavax Reports Second Quarter 2017 Financial Results

Dela

GAITHERSBURG, Md., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced its financial results for the second quarter and six months ended June 30, 2017.

Second Quarter and Subsequent Achievements:

  • Novavax' nanoparticle flu vaccine demonstrates superior immunogenicity and protection compared to market leader in preclinical challenge studies. In head-to-head comparison studies against Fluzone® High-Dose, Novavax' nanoparticle influenza vaccine with our proprietary Matrix-M(TM) adjuvant (NanoFlu) demonstrated significantly stronger and broader immune responses against matched and unmatched influenza strains, including a series of "drifted" strains evolved over more than a decade of influenza seasons. NanoFlu was also protective in an established challenge model against both a matched and a ten-year old unmatched strain. Further details will be published in the near future in a peer-reviewed journal and presented at scientific conferences.
     
  • Topline data from Phase 2 older adult safety and immunogenicity trial (E-205) demonstrated the benefit of adjuvanted formulations and two-dose regimens. Immunogenicity outcomes indicate both Matrix-M and aluminum phosphate adjuvants significantly increased the magnitude, duration and quality of the immune response relative to the RSV F antigen alone. All formulations and regimens were safe and well-tolerated. 
     
  • The Company announced the path forward for an adjuvanted RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) in older adults with plans to initiate a Phase 2 efficacy trial in 2018. This approach is driven by an observed 61% reduction in hospitalizations due to COPD exacerbations.
     
  • The Prepare(TM) clinical trial for infants via maternal immunization, supported by an $89 million grant from the Bill and Melinda Gates Foundation (BMGF), accelerated into the third global season of enrollment. Prepare's global footprint has grown from 16 sites in five countries in its first season of enrollment to 80 sites in 11 countries.
     
  • Data from the second of two Phase 2 trials of its RSV F Vaccine candidate confirmed an overall reduction of infection of >50% in women of childbearing age, published in the journal Vaccine.

Anticipated 2017 Event:

  • Initiation of a Phase 1/2 clinical trial of the Company's NanoFlu vaccine candidate in a head-to-head comparison to Fluzone High-Dose. Data from this trial should be available in the fourth quarter of 2017.

Summary

"Novavax has demonstrated considerable progress in our RSV F Vaccine program, highlighted by the continued strong execution of the Prepare trial, and the data from our recent trial in older adults, which confirmed the ability of the vaccine to generate robust immune responses and provided us with a development path forward," said Stanley C. Erck, President and CEO. "We are also excited by the recent preclinical results of our nanoparticle influenza vaccine and look forward to Phase 1/2 clinical data in the fourth quarter of this year."

Financial Results for the Three and Six Months Ended June 30, 2017

Novavax reported a net loss of $44.5 million, or $0.16 per share, for the second quarter of 2017, compared to a net loss of $79.4 million, or $0.29 per share, for the second quarter of 2016. For the six months ended June 30, 2017, the net loss was $88.3 million, or $0.32 per share, compared to a net loss of $156.6 million, or $0.58 per share, for the same period in 2016.

Novavax revenue in the second quarter of 2017 increased 169% to $6.7 million, compared to $2.5 million for the same period in 2016, primarily due to increased revenue recorded under the BMGF grant relating to our ongoing Prepare clinical trial.

Research and development expenses decreased 40% to $39.3 million in the second quarter of 2017, compared to $64.9 million for the same period in 2016. The decrease was primarily due to reduced costs associated with the clinical trials and development activities of our RSV F Vaccine and lower employee-related costs.

General and administrative expenses decreased 37% to $8.9 million in the second quarter of 2017, compared to $14.1 million for the same period in 2016. The decrease was primarily due to lower professional fees for pre-commercialization activities and lower employee-related costs.

Interest income (expense), net for the second quarter of 2017 was ($3.0) million, compared to ($2.8) million for the same period in 2016.

As of June 30, 2017, the company had $187.3 million in cash and cash equivalents and marketable securities compared to $235.5 million as of December 31, 2016. Net cash used in operating activities for the first six months of 2017 was $69.4 million, compared to $131.9 million for same period in 2016. The decrease in cash usage was primarily due to decreased costs relating to our RSV F Vaccine and lower overall employee-related costs.

Conference Call

Novavax management will host its quarterly conference call today at 4:30 p.m. ET. The dial-in number for the conference call is (877) 212-6076 (Domestic) or (707) 287-9331 (International), passcode 15614203. A replay of the conference call will be available starting at 7:30 p.m. ET on August 8, 2017 until 7:30 pm ET on August 15, 2017. To access the replay by telephone, dial (855) 859-2056 (Domestic) or (404) 537-3406 (International) and use passcode 15614203.

A webcast of the conference call can also be accessed via a link on the home page of the Novavax website (novavax.com) or through the "Investor Info"/"Events" tab on the Novavax website. A replay of the webcast will be available through the "Investor Info"/"Events" tab on the Novavax website until November 8, 2017.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2016 and the Quarterly Report on Form 10-Q for the period ended June 30, 2017, both as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

 
NOVAVAX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share information)
(unaudited)
                 
    Three Months Ended   Six Months Ended
    June 30,   June 30,
     2017     2016     2017     2016 
                 
Revenue   $     6,732     $   2,505     $     12,412     $   6,723  
                 
Expenses:                
Research and development      39,263       64,904       76,916       133,856  
General and administrative      8,940       14,099       17,793       24,627  
Total expenses     48,203       79,003       94,709       158,483  
Loss from operations     (41,471 )     (76,498 )     (82,297 )     (151,760 )
Interest income (expense), net     (2,993 )     (2,842 )     (6,032 )     (4,799 )
Other income (expense)     (1 )     (11 )     10       (44 )
Net loss   $     (44,465 )   $   (79,351 )   $     (88,319 )   $   (156,603 )
                 
Basic and diluted net loss per share   $     (0.16 )   $   (0.29 )   $     (0.32 )   $   (0.58 )
Basic and diluted weighted average                
number of common shares outstanding     283,444       270,760       278,836       270,469  
 


SELECTED CONSOLIDATED BALANCE SHEET DATA
(in thousands)
       
  June 30,
2017
  December 31,
2016
  (unaudited)    
Cash and cash equivalents $   75,793     $   144,353  
Marketable securities     111,515         91,126  
Total current assets     236,683         287,830  
Working capital     169,892         221,424  
Total assets     355,706         394,301  
Total notes payable and capital lease obligation     317,051         316,376  
Total stockholders' deficit     (59,062 )       (5,546 )

Contact:         

Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor Relations
ir@novavax.com
240-268-2000
               
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Russo Partners, LLC
David Schull
Maggie Beller
david.schull@russopartnersllc.com 
maggie.beller@russopartnersllc.com
212-845-4271  




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

BIMobject AB: Correction: BIMobject among fastest growing tech companies in EMEA18.12.2017 15:47Pressmeddelande

BIMobject comes in at place 185 in an objective ranking of the 500 fastest growing tech companies in Europe, the Middle East, and Africa. In a corresponding ranking of Swedish companies, BIMobject places 24 th out of 50.  The Deloitte Technology Fast 500(TM) EMEA programme is an objective industry ranking that compares and lists the fastest growing technology companies in Europe, the Middle East, and Africa during the past four years. The 2017 winners were selected based on percentage fiscal-year revenue growth from 2013 to 2016. The regional ranking Sweden Technology Fast 50 lists the fastest growing companies in the Swedish tech industry.  "Our places in the Deloitte rankings are great news proving that our expansion strategy works. The BIMobject Cloud is now the world's leading platform for digital building products. That's the kind of innovation that drives us while we keep working towards growth", says Stef

BIMobject AB: Rättelse: BIMobject bland de snabbast växande techbolagen i EMEA18.12.2017 15:47Pressmeddelande

BIMobject hamnar på plats 185 i objektiv rankning av de 500 snabbast växande techföretagen i Europa, Mellanöstern och Afrika. I motsvarande rankning av svenska företag tilldelas BIMobject plats 24 av 50.  Programmet Deloitte Technology Fast 500(TM) EMEA är en objektiv branschrankning som jämför och listar de snabbast växande techföretagen i Europa, Mellanöstern och Afrika under de senaste fyra åren. Vinnarna för år 2017 valdes ut baserat på procentandelen inkomsttillväxt under räkenskapsåren 2013 till 2016. Den regionala rankningen Sweden Technology Fast 50 listar de snabbast växande företagen inom den svenska techbranschen.  "Våra placeringar i Deloittes rankningar är jätteroliga nyheter som visar att vår strategi för expansion håller. Molnlösningen BIMobject Cloud är nu världens ledande plattform för digitala byggobjekt. Det är sådan innovation vi drivs av samtidigt som vi fortsätter hålla siktet inställt på tillväxt", säger Stefan Larsson, VD och gru

BIMobject AB: BIMobject bland de snabbast växande techbolagen i EMEA18.12.2017 15:18Pressmeddelande

BIMobject hamnar på plats 158 i objektiv rankning av de 500 snabbast växande techföretagen i Europa, Mellanöstern och Afrika. I motsvarande rankning av svenska företag tilldelas BIMobject plats 24 av 50.  Programmet Deloitte Technology Fast 500(TM) EMEA är en objektiv branschrankning som jämför och listar de snabbast växande techföretagen i Europa, Mellanöstern och Afrika under de senaste fyra åren. Vinnarna för år 2017valdes ut baserat på procentandelen inkomsttillväxt under räkenskapsåren 2013 till 2016. Den regionala rankningen Sweden Technology Fast 50 listar de snabbast växande företagen inom den svenska techbranschen.  "Våra placeringar i Deloittes rankningar är jätteroliga nyheter som visar att vår strategi för expansion håller. Molnlösningen BIMobject Cloud är nu världens ledande plattform för digitala byggobjekt. Det är sådan innovation vi drivs av samtidigt som vi fortsätter hålla siktet inställt på tillväxt", säger Stefan Larsson, VD och grun

BIMobject AB: BIMobject among fastest growing tech companies in EMEA18.12.2017 15:18Pressmeddelande

BIMobject comes in at place 158 in an objective ranking of the 500 fastest growing tech companies in Europe, the Middle East, and Africa. In a corresponding ranking of Swedish companies, BIMobject places 24 th out of 50.  The Deloitte Technology Fast 500(TM) EMEA programme is an objective industry ranking that compares and lists the fastest growing technology companies in Europe, the Middle East, and Africa during the past four years. The 2017 winners were selected based on percentage fiscal-year revenue growth from 2013 to 2016. The regional ranking Sweden Technology Fast 50 lists the fastest growing companies in the Swedish tech industry.  "Our places in the Deloitte rankings are great news proving that our expansion strategy works. The BIMobject Cloud is now the world's leading platform for digital building products. That's the kind of innovation that drives us while we keep working towards growth", says Stef

SD-WAN Market Leader, Aryaka, Releases First EMEA Edition of its State of SD-WAN Connectivity Report18.12.2017 15:06Pressmeddelande

Research finds up to 20x cloud and SaaS application performance improvements when connecting via private network-based SD-WANs versus the public Internet LONDON, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, has released its first EMEA Edition of the State of SD-WAN Connectivity report that analyses the performance of SD-WAN deployments over the Internet as compared with those delivered over global private networks. The report highlights specific application response times between various European, Middle East, Asia-Pacific and Americas locations, as well as key factors that impact the performance of cloud and SaaS applications. This research helps IT leaders in Europe, Middle East and Africa (EMEA) to evaluate the best underlying connectivity for their SD-WAN deployments to ensure fast, reliable and consistent performance for all on-premises, cloud and SaaS applications, including voice, video, and data. The report reveals significant dif

Navigators to Acquire Belgian Specialty Insurer18.12.2017 07:30Pressmeddelande

STAMFORD, CT, December 18, 2017 - The Navigators Group, Inc. (NASDAQ:NAVG) today announced that it has entered into a share purchase agreement for the purchase of all of the shares of Assurances Continentales - Continentale Verzekeringen NV ("ASCO") and Bracht, Deckers & Mackelbert NV ("BDM").  ASCO and BDM are both based in Antwerp, Belgium. The proposed acquisition is part of Navigators' strategy of expanding its well-established specialty insurance expertise to more brokers and insureds across Europe. ASCO is a specialty insurance company offering marine and property and casualty insurance. BDM is an insurance underwriting agency that underwrites risk coverage in niche markets on behalf of ASCO and a number of major international insurers. Additionally, as part of the transaction, Navigators will acquire all the shares of Canal Re SA, a Luxembourg reinsurance company that is a wholly-owned subsidiary of ASCO.  The acquisition reinforces Navigators' presence in the European Un

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum